News >

ASCO Studies Refine CAR T Cell Use

Silas Inman @silasinman
Published: Thursday, Jun 07, 2018

Frederick L. Locke, MD

Frederick L. Locke, MD
Several studies presented at the 2018 ASCO Annual Meeting helped further refine and inform treatment strategies for the budding class of chimeric antigen receptor (CAR) T-cell therapies, with a focus on predicting adverse events (AEs) and optimizing efficacy.

This analysis showed that patients with Philadelphia chromosome (Ph)-like genetic characteristics were highly unlikely to experience grade 4 or 5 cytokine release syndrome (CRS) or neurotoxicity.

Durability of Response

With the rapid develop of the CAR T-cell therapies, the durability of response and impact on long-term outcomes remains a question of interest, particularly as it factors into a value equation. As data from the clinical trials matures, it is becoming clear that patients experiencing a CR at month 3 to 6 are likely to experience a long-term remission.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x